Real-world experience with odevixibat in children with progressive familial intrahepatic cholestasis

Published data on the use of odevixibat in a real-world scenario are lacking. We explored the effectiveness of odevixibat in a heterogenous cohort of children diagnosed with PFIC (including patients with classic as well as rarer types of PFIC, and with advanced liver disease and associated comorbidities). Our results demonstrate that odevixibat is effective for the treatment of cholestasis and pruritus in children with different PFIC subtypes in a real-life scenario. These results support the use of odevixibat in children with any type of PFICs, including those with different stages of liver disease and comorbidities.

Authors

Institutions

Publication Details

Journal
JHEP Reports
Published
2024-12-20
DOI
https://doi.org/10.1016/j.jhepr.2024.101309
Citations
6
Primary Topic
Pediatric Hepatobiliary Diseases and Treatments
Type
article
Field-Weighted Citation Impact
3.44
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Real-world experience with odevixibat in children with progressive familial intrahepatic cholestasis

Giuseppe Indolfi, Angelo Di Giorgio, Claudia Mandato, Greta Carioli et al.
6 citations
JHEP Reports
Pediatric Hepatobiliary Diseases and Treatments
3.44
article

Real-world experience with odevixibat in children with progressive familial intrahepatic cholestasis

Giuseppe Indolfi, Angelo Di Giorgio, Claudia Mandato, Greta Carioli, Emanuele Nicastro, Maurizio Fuoti, Marco Sciveres, Lorenzo D’Antiga, Federica Nuti, Ana Lleò, Pier Luigi Calvo, Annalisa Madeo, Arianna Ghirardi, Simona Gatti, Mara Cananzi, Chiara Zanchi
article en
6 citations

Abstract

Published data on the use of odevixibat in a real-world scenario are lacking. We explored the effectiveness of odevixibat in a heterogenous cohort of children diagnosed with PFIC (including patients with classic as well as rarer types of PFIC, and with advanced liver disease and associated comorbidities). Our results demonstrate that odevixibat is effective for the treatment of cholestasis and pruritus in children with different PFIC subtypes in a real-life scenario. These results support the use of odevixibat in children with any type of PFICs, including those with different stages of liver disease and comorbidities.

JHEP ReportsVol. 7(4)
Marche Polytechnic University (IT), University of Salerno (IT), Humanitas University (IT), University of Padua (IT), IRCCS Materno Infantile Burlo Garofolo (IT), Istituto Giannina Gaslini (IT), Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT), Azienda Ospedaliera Citta' della Salute e della Scienza di Torino (IT), Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (IT), Ospedale Papa Giovanni XXIII (IT), Meyer Children's Hospital (IT), Bambino Gesù Children's Hospital (IT), Istituti di Ricovero e Cura a Carattere Scientifico (IT), IRCCS Humanitas Research Hospital (IT), Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione (IT), University of Milano-Bicocca (IT)
Zero hunger
Openalex Percentile: Top 7%
Pediatric Hepatobiliary Diseases and Treatments
3.44
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.